Recombinant Carboxypeptidase B Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable, designated model rCPB-PG-100, is a zinc-dependent metalloprotease assigned EC 3.4.17.2. It is manufactured from a defined Escherichia coli production strain under EU GMP Part II and ICH Q7 conditions. The enzyme hydrolyses C-terminal arginine and lysine residues from peptides and proteins. In therapeutic protein manufacturing, this reaction is applied after trypsin-mediated cleavage of proinsulin and single-chain precursors to remove residual basic amino acids from the B-chain terminus and to generate the native active two-chain hormone. The product is released as a white to off-white lyophilized powder. Supplied with a certificate of analysis, the product is tested for specific activity, purity by SDS-PAGE, residual host cell protein, residual host cell DNA, bioburden, and bacterial endotoxin. The recombinant production route removes pancreas-derived raw material and reduces the viral and TSE risk associated with animal-sourced carboxypeptidase B.

What Limits Recombinant Carboxypeptidase B Activity in Proinsulin Processing?

In proinsulin processing, trypsin cleaves after paired basic residues in the C-peptide junctions, leaving exposed C-terminal lysine or arginine. Recombinant carboxypeptidase B removes these residues in a zinc-dependent reaction. Specific activity is assigned using hippuryl-L-arginine at 25 °C and pH 7.65; the liberated hippuric acid is measured at 254 nm. Typical release material for model rCPB-PG-100 carries a specific activity of ≥ 120 U/mg, although lot-specific limits govern and published data for this specific configuration is limited. The solution reaction is maintained at 20–35 °C and pH 7.0–8.5. Above 37 °C, autolysis and target-protein deamidation can become significant within 4 h; prolonged processing therefore requires degradation studies for the specific target protein.

Scale-up is executed in jacketed stainless steel reactors with low-shear impeller mixing at 50–150 rpm. High shear and vortexing are avoided because interfacial denaturation reduces enzymatic activity. After conversion, the target protein is separated from the enzyme by chromatography or tangential flow filtration using 10 kDa regenerated cellulose cassettes. Transmembrane pressure is held below 1.0 bar to limit membrane fouling. Clearance of residual carboxypeptidase B from the target protein is monitored by ELISA or LC-MS/MS; a typical acceptance limit for residual enzyme in the drug substance is no more than 10 ppm, but the limit is adjusted to the clinical dose and route.

Model rCPB-PG-100 is supplied in USP Type I glass vials with bromobutyl closures. The lyophilized plug is reconstituted in 20 mM Tris-HCl, 100 mM NaCl, pH 8.0 to a target of 1–10 mg/mL. The zinc cofactor is necessary for catalytic activity. Diluents containing EDTA, citrate, or high phosphate should not be used because chelation of the active-site zinc causes activity loss. Where phosphate is unavoidable, total phosphate is maintained below 10 mM unless zinc supplementation is quantitatively validated. Reconstituted solution is held at 2–8 °C for no more than 24 h. Repeated freeze-thaw cycles are not recommended; three cycles have been associated with activity loss greater than 15% in routine site comparability studies.

Long-term storage is at 2–8 °C in sealed, desiccated packaging. Exposure to relative humidity above 60% during dispensing should be avoided because the lyophilized powder is hygroscopic and moisture-induced aggregation can reduce activity. If dispensing requires longer than 30 min, a dry nitrogen environment is recommended. Reducing agents such as dithiothreitol or beta-mercaptoethanol at concentrations used for protein reduction can destabilize intramolecular disulfide bonds and should be avoided unless the reaction is intentionally performed under controlled conditions with subsequent refolding.

Release Specifications and the Control of Process-Derived Impurities

The release specification is structured under ICH Q6B for biotechnological products and uses pharmacopoeial general chapters. The values in the table below are representative for model rCPB-PG-100 and are not a substitute for the lot certificate of analysis. Residual host cell DNA is quantified by qPCR calibrated against a process-specific E. coli DNA standard. Host cell protein is measured by a process-specific ELISA with a detection limit of 0.5 ppm. Endotoxin testing follows Ph.Eur. 2.6.14 and USP <85>; bioburden testing follows Ph.Eur. 2.6.12.

Residual host cell protein and DNA limits are batch-specific and aligned to the intended downstream purification and clinical dose. For injectable applications, the product is not released as sterile; downstream sterile filtration is required. If a sterility test is requested, membrane filtration according to Ph.Eur. 2.6.1 is applied to the reconstituted bulk only after formulation and filtration. The product is supported by a drug master file and a TSE/BSE statement because the manufacturing process uses no animal-derived raw materials. The quality system is maintained under ISO 9001:2015.

When the Product Is Transferred to Solid Oral or Injectable Route Development

For injectable route development, terminal moist heat at 121 °C and gamma irradiation are not compatible with catalytic activity. Sterile filtration through a 0.22 µm PVDF membrane after reconstitution is the standard operation. Filtration compatibility should be confirmed; adsorption to unmodified hydrophobic membranes can reduce activity by 10–30% if a stabilizer is absent. Aqueous injectable matrices are buffered at pH 7.0–8.0. Below pH 4.0, tertiary structure is lost and zinc dissociates, with irreversible activity loss that cannot be recovered by neutralization alone.

In tablet, capsule, or granule dosage forms, the enzyme is subject to gastric acid and pepsin if administered orally. Published data describing intact oral absorption of carboxypeptidase B are limited; therefore, a protective enteric coating is required if the enzyme is intended to act beyond the stomach. Dissolution of an enteric coating can be evaluated with USP <711> two-stage dissolution. Direct compression of the lyophilized powder is constrained by bulk density in the range of 0.2–0.4 g/mL and by poor flow. Dry granulation or roller compaction is preferred over wet granulation. If fluid-bed granulation is used, inlet air is maintained below 35 °C and product temperature below 25 °C; activity assay after drying is mandatory because published stability data for this specific solid configuration are limited. If direct compression is attempted, a rotary tablet press with precompression force below 5 kN is used to avoid lamination. Tablet breaking force is monitored by USP <1217> and friability by USP <1216>.

Comparative Data Are Generated from Side-by-Side Process Runs

Pancreas-derived carboxypeptidase B from porcine tissue carries a raw-material risk of animal virus and TSE and shows batch-to-batch variation in co-purifying carboxypeptidase A and elastase activities. The recombinant E. coli process eliminates pancreas-derived raw material and reduces co-purifying proteases to below the detection limit of a chromogenic substrate assay. Because the recombinant enzyme is expressed in a bacterial host, it lacks mammalian glycan motifs such as α-1,3-galactose and Neu5Gc; this reduces immunogenicity concerns when carryover into injectable products is assessed. Other recombinant processes may use yeast or mammalian hosts and require different host cell impurity profiling. Compared with an animal-derived preparation, a change to recombinant material under ICH Q5E requires comparability of identity, specific activity, impurity profile, and process clearance.

Production-scale purification of model rCPB-PG-100 uses a two-step chromatography sequence of strong anion exchange and hydrophobic interaction. The main batch failure mode observed on scale-up is not loss of catalytic activity but aggregation at air-liquid interfaces in low-volume hold tanks. A nitrogen overlay and avoidance of vortex formation control aggregate content below 2% by size-exclusion HPLC. Diafiltration into formulation buffer is performed with 10 kDa regenerated cellulose cassettes at transmembrane pressure below 1.0 bar. Residual moisture after lyophilization is controlled to ≤ 5.0% and verified by Ph.Eur. 2.2.32; higher moisture accelerates aggregate formation and shortens assigned shelf life.

The product is not compatible with strong oxidants, metal-chelating buffers above the stated thresholds, acidic conditions below pH 4.0, or high shear operations such as high-pressure homogenization. It should not be terminally sterilized by heat or radiation. Because the product is not released as sterile, injectable applications require an additional filtration step. Published data for this specific configuration in finished solid dosage forms are limited; each formulation route requires route-specific activity and degradation studies under ICH Q1A for stability.